New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma

Restricted access

The NCCN Guidelines Panel for Melanoma debuted new guidelines for uveal melanoma at the NCCN 23rd Annual Conference. Although uveal melanoma and cutaneous melanoma share the same name, they do have different characteristics and treatments. The NCCN Guidelines describe how tumor size guides therapeutic options, which for most tumors is radiotherapy. Predictors of melanoma-related mortality include advanced age, larger tumor size, and histopathologic and molecular features. The NCCN Guidelines for Cutaneous Melanoma have not changed notably, but adjuvant therapy with immunotherapies is now recommended. The best second-line treatment in the metastatic setting remains unclear.

Correspondence: Christopher A. Barker, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY 10065. Email: barkerc@mskcc.org; and April K. Salama, MD, Division of Medical Oncology, Duke University School of Medicine, DUMC 3198, Durham, NC 27710. Email: april.salama@duke.edu
  • 1.

    Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118:18811885.

  • 2.

    Mortality in patients with small choroidal melanoma. COMS report No. 4. Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997;115:886893.

    • Search Google Scholar
    • Export Citation
  • 3.

    Factors predictive of growth and treatment of small choroidal melanoma: COMS report No. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997;115:15371544.

    • Search Google Scholar
    • Export Citation
  • 4.

    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:16841693.

    • Search Google Scholar
    • Export Citation
  • 5.

    Melia M, Moy CS, Reynolds SM. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS report No. 3. Arch Ophthalmol 2006;124:226238.

    • Search Google Scholar
    • Export Citation
  • 6.

    Hawkins BSCollaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004;138:936951.

    • Search Google Scholar
    • Export Citation
  • 7.

    Ribas A, Puzanov I, Dummer R. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Lancet Oncol 2015;16:908918.

    • Search Google Scholar
    • Export Citation
  • 8.

    Friedman CF, Navid-Azarbaijani P, Shoushtari AN. Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single institution under an expanded-access program (EAP) [abstract]. J Clin Oncol 2016;34(Suppl15):Abstract 9519.

    • Search Google Scholar
    • Export Citation
  • 9.

    Johnson DB, Pectasides E, Feld E. Sequencing treatment in BRAFV600 mutant melanoma: anti-pd-1 before and after BRAF inhibition. J Immunotherapy 2017;40:3135.

    • Search Google Scholar
    • Export Citation
  • 10.

    Ackerman A, Klein O, McDermott DF. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120:16951701.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1931 1430 138
PDF Downloads 775 558 30
EPUB Downloads 0 0 0